Delcath to sell 9 million units in $30 million public offering

Bookrunner Roth offers units of one common share and 1.75 warrants

By Devika Patel

Knoxville, Tenn., July 15 – Delcath Systems Inc. will sell 9 million units in a public offering, according to a Form S-1/A filed Wednesday with the Securities and Exchange Commission. The company has registered up to $30 million of stock for the deal, which was announced on June 15.

The units will each consist of one common share and 1.75 warrants. One warrant expires in 90 days and the other expires in five years.

Roth Capital Partners is the bookrunner.

Proceeds will be used for clinical studies, commercialization, research, capital expenditures, working capital and other general corporate purposes.

Delcath is based in Stamford, Conn., where it develops isolated perfusion technology for organ or region-specific delivery of therapeutic agents.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.